Strides Pharma Science Ltd (IN:STAR)
:STAR
Want to see IN:STAR full AI Analyst Report?
Top Page
Strides Pharma Science Ltd
(STAR)
Select Model
Select Model
Rating:74Outperform
Price Target:
₹1,108.00
▲(16.54% Upside)
Action:Upgraded
Date:05/21/26
The score is driven primarily by improving fundamentals (profitability turnaround and better leverage), tempered by weaker/volatile free-cash-flow conversion. Strong technical uptrend supports the setup, while valuation is favorable given the low P/E and the provided high dividend yield.
Positive Factors
Profitability Turnaround
The company moved from losses in 2022–2024 to solid profits in 2025–2026, with gross margin around 36% and net margin ~11%. This turnaround indicates restored operating leverage and execution, supporting sustainable earnings power if margins are maintained.
Negative Factors
Cash Flow Quality
Free cash flow is volatile and weakened in 2026, with FCF only about 22% of net income and a ~50% YoY drop. That weak conversion limits internal funding for capex, dividends or debt paydown and raises execution risk if cash generation slips again.
Read all positive and negative factors
Positive Factors
Negative Factors
Profitability Turnaround
The company moved from losses in 2022–2024 to solid profits in 2025–2026, with gross margin around 36% and net margin ~11%. This turnaround indicates restored operating leverage and execution, supporting sustainable earnings power if margins are maintained.
Read all positive factors
Strides Pharma Science Ltd (STAR) vs. iShares MSCI India ETF (INDA)
Market Cap
₹100.04B
Dividend Yield0.41%
Average Volume (3M)12.54K
Price to Earnings (P/E)18.3
Beta (1Y)0.86
Revenue Growth4.88%
EPS Growth66.43%
CountryIN
Employees3,065
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)43.13
Shares Outstanding92,172,714
10 Day Avg. Volume13,417
30 Day Avg. Volume12,536
Financial Highlights & Ratios
PEG Ratio0.42
Price to Book (P/B)2.78
Price to Sales (P/S)1.78
P/FCF Ratio71.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)71.07
Revenue Forecast (FY)₹57.61B
Strides Pharma Science Ltd Business Overview & Revenue Model
Company Description
Strides Pharma Science Limited is a pharmaceutical company that focuses on the development, production, and worldwide commercialization of medicinal products. Its extensive global footprint spans Africa, Australia, North America, Europe, Asia, Ind...
How the Company Makes Money
Strides primarily makes money by selling generic pharmaceutical products, with revenue largely derived from finished dosage formulations (e.g., tablets, capsules, and other dose forms) manufactured in its facilities and sold into various domestic ...
Strides Pharma Science Ltd Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
68
Positive
Cash Flow
55
Neutral
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 46.85B | 48.59B | 44.75B | 38.28B | 36.68B | 30.59B |
| Gross Profit | 16.59B | 17.69B | 11.83B | 8.51B | 8.05B | 4.11B |
| EBITDA | 8.87B | 10.50B | 9.27B | 3.78B | 2.17B | -2.45B |
| Net Income | 3.97B | 5.56B | 4.05B | -1.20B | -2.21B | -4.60B |
Balance Sheet | ||||||
| Total Assets | 65.21B | 69.27B | 60.49B | 58.40B | 66.38B | 69.76B |
| Cash, Cash Equivalents and Short-Term Investments | 2.27B | 4.10B | 2.06B | 2.90B | 3.61B | 1.84B |
| Total Debt | 18.44B | 17.58B | 18.80B | 25.17B | 30.30B | 30.25B |
| Total Liabilities | 37.18B | 37.78B | 34.62B | 37.68B | 44.66B | 45.93B |
| Stockholders Equity | 27.56B | 31.08B | 25.52B | 21.26B | 22.12B | 23.59B |
Cash Flow | ||||||
| Free Cash Flow | 2.42B | 1.21B | 4.42B | 5.83B | -505.27M | -4.01B |
| Operating Cash Flow | 3.91B | 5.39B | 6.84B | 7.01B | 444.11M | -2.58B |
| Investing Cash Flow | -1.48B | -1.78B | -896.89M | -1.50B | 3.02B | -1.19B |
| Financing Cash Flow | -2.33B | -2.85B | -6.43B | -6.93B | -2.14B | 4.21B |
Strides Pharma Science Ltd Technical Analysis
Positive
950.75
Price Trends
1069.24
Positive
971.06
Positive
928.85
Positive
Market Momentum
-10.47
Positive
55.02
Neutral
83.08
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:STAR, the sentiment is Positive. The current price of 950.75 is below the 20-day moving average (MA) of 1089.17, below the 50-day MA of 1069.24, and above the 200-day MA of 928.85, indicating a bullish trend. The MACD of -10.47 indicates Positive momentum. The RSI at 55.02 is Neutral, neither overbought nor oversold. The STOCH value of 83.08 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:STAR.
Strides Pharma Science Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | ₹4.33T | 37.68 | ― | 0.91% | 11.19% | 5.01% | |
74 Outperform | ₹100.04B | 18.28 | ― | 0.41% | 4.88% | 66.43% | |
68 Neutral | ₹817.19B | 23.15 | ― | 0.33% | 6.08% | 0.77% | |
67 Neutral | ₹1.07T | 24.84 | ― | 0.63% | 3.19% | -24.30% | |
60 Neutral | ₹750.02B | 83.61 | ― | 0.15% | 22.67% | 147.77% | |
60 Neutral | ₹222.32B | -63.27 | ― | 0.08% | -3.08% | -458.85% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:STAR
Strides Pharma Science Ltd
1,102.25
240.64
27.93%
IN:AUROPHARMA
Aurobindo Pharma Ltd
1,395.10
289.75
26.21%
IN:DRREDDY
Dr. Reddy's Laboratories Ltd.
1,277.05
-33.59
-2.56%
IN:LAURUSLABS
Laurus Labs Ltd.
1,375.95
716.55
108.67%
IN:PPLPHARMA
Piramal Pharma Limited
163.75
-31.17
-15.99%
IN:SUNPHARMA
Sun Pharmaceutical Industries Limited
1,800.65
167.82
10.28%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.